There are 1.5 million new cases of Alzheimer’s disease reported every year in Europe and North America. Often those affected by the disease, and their spouses hide the disease for as long as possible from adult children. Once, a diagnosis is made based on the patients performance on a cognitive skills test (MMSE) family members need to begin making plans for the care of the patient. However, these new care providers do not know how quickly cognitive decline will progress, or how long the affected person has been exhibiting symptoms.

The new Aptamarker AD fingerprint will provide needed personalized information in three ways;

– Earlier diagnosis of the disease (prior to significant cognitive decline)

– Characterization of disease severity

– Prediction of rate of cognitive decline

Each patient will have their own unique AD fingerprint, but our algorithms will characterize each aspect of the disease in terms of how each fingerprint compares to our dataset of fingerprints.